Toward the quantitative prediction of T-cell epitopes: QSAR studies on peptides having affinity with the class I MHC Molecular HLA-A*0201

Journal of Computational Biology

Volumn 11, Issue 4, 2004, Pages 683-694

  Zhihua, Lin ^a,b   Wu, Yuzhang ^a   Bo, Zhu ^a   Ni, Bing ^a   Li, Wang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

3D QSAR; Binding affinity; Epitope prediction; HLA A*0201; Structural characterization

Indexed keywords

AMINO ACID; EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; EPITOPES; HLA-A ANTIGENS; HUMANS; KINETICS; PEPTIDES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 4544285154     PISSN: 10665277     EISSN: None     Source Type: Journal    
DOI: 10.1089/cmb.2004.11.683     Document Type: Article

References (50)

1. Bertoni, R., Sidney, J., Flower, P., Chesnut, R.W., Chisari, F.V., and Sette, A. 1997. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin. Invest. 100, 503-513.
2. Blythe, M.J., Doytchinova, I.A., and Flower, D.R. 2002. JenPep: A database of quantitative functional peptide data for immunology. Bioinformatics 18, 434-439.
3. Brusic, V., Bucci, K., Schonbach, C., Petrovsky, N., Zeleznikow, J., and Kazura, J.W. 2001. Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding. J. Mol. Graph Model. 19, 405-411, 467.
4. Brusic, V., Rudy, G., Honeyman, M., Hammer, J., and Harrison, L. 1998. Prediction of MHC class II-binding peptides using evolutionary algorithm and artificial neural network. Bioinformatics 14, 121-130.
5. Collantes, E.R., and Dunn, W.J. 1995. Amino acid side chain descriptors for quantitative structure activity relationship studies of peptide analogues. J. Med. Chem. 38, 2705-2713.
6. Cramer, R.D., Patterson, D.E., and Bunce, J.D. 1988. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110, 5959-5967.
7. D'Amaro, J., Houbiers, J.G., Drijfhout, J.W., Brandt, R.M., Schipper, R., Bavinck, J.N., Melief, C.J., Kast, W.M., Doytchinova, I.A., and Paine, K. 1995. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum. Immunol. 43, 13-18.
8. Davenport, M.P., Ho Shon, I.A., and Hill, A.V. 1995. An empirical method for the prediction of T-cell epitopes. Immunogenetics 42, 392-397.
9. Del Guercio, M.-F., Sidney, J., Hermanson, G., Perez, C., Grey, H.M., Kubo, R.T., and Sette, A. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154, 685-693.
10. Doytchinova, I.A., and Flower, D.R. 2001. Toward the quantitative prediction of T-cell epitopes: CoMFA and CoMSIA studies of peptides with affinity for the class I MHC molecule HLA-A*0201. J. Med. Chem. 44, 3572-3581.
11. Doytchinova, I.A., and Flower, D.R. 2002a. Quantitative approaches to computational vaccinology. Immunol. Cell Biol. 80, 270-279.
12. Doytchinova, I.A., and Flower, D.R. 2002b. Physicochemical explanation of peptide binding to HLA-A*0201 major histocompatibility complex: A three-dimensional quantitative structure-activity relationship study. Proteins 48, 505-518.
13. Drijfhout, J.W., Brandt, R.M., D'Amaro, J., Kast, W.M., and Melief, C.J. 1995. Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Human Immunol. 43, 1-12.
14. Falk, K., Rotzschke, O., Stefanovic, S., Jung, G., and Rammensee, H.-G. 1991. Allele specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296.
15. Franco, A., Tilly, D.A., Gramaglia, I., Croft, M., Cipolla, L., Meldal, M., and Grey, H.M. 2000. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nature Immunol. 1, 145-149.
16. Froloff, N., Windemuth, A., and Honig, B. 1997. On the calculation of binding free energy using continuum methods: Application to MHC class I protein-peptide interactions. Protein Sci. 6, 1293-1301.
17. Goodford, P.J. 1985. A computational precedure for determining energetically favorable binding sites on biologically important molecules. J. Med. Chem. 28, 849-857.
18. Grigoras, S. 1985. A new semiempirical method for the calculation of the partition coefficient. Ph.D. thesis, University of Illinois at Chicago, Chicago, IL.
19. Honeyman, M.C., Brusic, V., Stone, N.L., and Harrison, L.C. 1998. Neutral network-based prediction of candidate T-cell epitopes. Nature Biotechnol. 16, 966-969.
20. Jager, E., Jager, D., and Knuth, A. 1999. CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 18, 143-150.
21. Jian, A.N., Koile, K., and Chapman, D. 1994. Compass: Predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. J. Med. Chem. 37, 2315-2327.
22. Kast, W.M., Brandt, R.M.P., Sidney, J., Drijfhout, J.-W., Kubo, R.T., Grey, H.M., Melief, C.J.M., and Sette, A. 1994. Pole of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3911.
23. Katritzky, A.R., Maran, U., Lobanov, V.S., and Karelson, M. 2000. Perspective: Structurally diverse quantitative structure-property relationship correlations of technologically relevant physical properties. J. Chem. Inf. Comput. Sci. 40, 1-18.
24. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E., and Rosenberg, S.A. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968.
25. Klebe, G., Abraham, U., and Mietzner, T. 1994. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37, 4130-4146.
26. Kubo, R.T., Sette, A., Grey, H.M., Appella, E., Sakaguchi, K., Zhu, N.-Z., Arnott, D., Sherman, N., Shabanowitz, J., Michel, H., Bodnar, W.M., Davis, T.A., and Hunt, D.F. 1994. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol. 152, 3913-3924.
27. Mallios, R.R. 1999. Class II MHC quantitative binding motifs derived from a large molecular database with a versatile iterative stepwise discriminate analysis meta-algorithm. Bioinformatics 15, 432-439.
28. Mamitsuka, H. 1998. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Protein 33, 460-474.
29. Meister, G.E., Roberts, C.G.P., Berzofsky, J.A., and De Groot, A.S. 1995. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13, 581-591.
30. Parker, K.C., Bednarek, M.A., and Coligan, J.E. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175.
31. Parker, K.C., Bednarek, M.A., Hull, L.K., Utz, U., Cunningham, B., Zweerink, H.J., Biddison, W.E., and Coligan, J.E. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J. Immunol. 149, 3580-3587.
32. Parkhurst, M.R., Fitzgerald, E.B., Southwood, S., Sette, A., Rosenberg, S.A., and Kawakami, Y. 1998. Identification of a shared HLA-A*0201- restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895-4901.
33. Parkhurst, M.R., Salgaller, M.L., Southwood, S., Robbins, P.F., Sette, A., Rosenberg, S.A., and Kawakami, Y. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157, 2539-2548.
34. Rammensee, H.G., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanovic, S. 1999. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219.
35. Rammensee, H.G., Friede, T., and Stevanoviic, S. 1995. MHC ligands and peptide motifs: First listing. Immunogenetics 41, 178-228.
36. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P.F., Marincola, F.M., Salgaller, M.L., Yannelli, J.R., Appella, E., and Rosenberg, S.A. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154, 2257-2265.
37. Robinson, D.D., Winn, P.J., Lyne, P.D., and Richards, W.G. 1999. Self-organizing molecular field analysis: A tool for structure-activity studies. J. Med. Chem. 42, 573-583.
38. Rognan, D., Scapozza, L., Folkers, G., and Daser, A. 1994. Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. Biochemistry 33, 11476-11485.
39. Rongcun, Y., Salazar-Onfray, P., Charo, J., Malmberg, K.-J., Evrin, K., Maes, H., Hising, C., Petersson, M., Larsson, O., Lan, L., Appella, E., Sette, A., Celis, E., and Kiessling, R. 1999. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163, 1037-1044.
40. Ruppert, J., Sidney, J., Celis, E., Kubo, R.T., Grey, H.M., and Sette, A. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A*0201 molecules. Cell 74, 929-937.
41. Schonbach, C., Kun, Y., and Brusic, V. 2002. Large-scale computational identification of HIV T-cell epitopes. Immunol. Cell Biol. 80, 300-306.
42. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W.M., Melief, C.J.M., Oseroff, C., Yuan, L., Ruppert, J., Sidney, J., del Guercio, M.-F., Southwood, S., Kubo, R.T., Chesnut, R.W., Grey, H.M., and Chisari, F.V. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592.
43. Sezerman, U., Vajda, S., and DeLisi, C. 1996. Free energy mapping of class I MHC molecules and structural determination of bound peptides. Protein Sci. 5, 1272-1281.
44. Sung, M.H., Zhao, Y., Martin, R., and Simon, R. 2002. T-cell epitope prediction with combinatorial peptide libraries. J. Comput. Biol. 9, 527-539.
45. Toh, H., Kamikawaji, N., Tana, T., Muta, S., Sasazuki, T., and Kuhara, S. 2000. Magnitude of structure changes of the T-cell receptor binding regions determine the strength of T-cell antagonism: Molecular dynamics simulation of HLA-DR4 (DRB1*0405) complexed with analogue peptide. Protein Eng. 13, 423-429.
46. Tsai, V., Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., and Celis, E. 1997. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158, 1796-1802.
47. Vitiello, A., Sette, A., Yuan, L., Farrness, P., Southwood, S., Sidney, J., Chesnut, R.W., Grey, H.M., and Liningston, B. 1997. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: Implications on immunogenicity and immunodominance. Eur. J. Immunol. 27, 671-678.
48. Wang, R.F., and Rosenberg, S.A. 1999. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85-100.
49. Zhang, C., Anderson, A., and DeLisi, C. 1998. Structural principles that govern the peptide-binding motifs of class I MHC molecules. J. Mol. Biol. 281, 929-947.
50. Zoller, M., and Matzku, S. 1999. Cancer therapy, new concepts on active immunization. Immunobiol. 201, 1-21.